Donald Lamm

Donald Lamm, MD completed his undergraduate education at the University of California, Los Angeles. Dr. Lamm received his medical degree from David Geffen School of Medicine at UCLA and completed his residencies at University of California at Los Angeles Wadsworth Veterans Administration Medical Center in general surgery and the University of California at San Diego in urology. Dr. Lamm has had a lifelong interest in Urologic Oncology and clinical trials with a particular interest in immunotherapy and chemoprevention. Dr. Lamm was awarded the initial NIH-funded contract to evaluate BCG immunotherapy of superficial bladder cancer in a randomized clinical trial (1978). This work, accruing 231 patients, resulted in the first controlled trial demonstrating the efficacy of intravesical BCG immunotherapy. His subsequent NIH-funded research demonstrated the superiority of intravesical BCG over oral administration and the efficacy of intravesical without percutaneous BCG immunotherapy. Subsequent SWOG studies under his direction showed BCG immunotherapy to be superior to doxorubicin and mitomycin chemotherapy.